Merck & Co., Inc. Cash & Equivalents 2006-2025 | MRK
What is cash & equivalents?
Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.
What is Merck & Co., Inc.'s current cash & equivalents?
Merck & Co., Inc. (MRK) annual cash & equivalents for 2024 was $13.32B, a 92.76% increase from 2023. Merck & Co., Inc. cash & equivalents for the quarter ending September 30, 2025 was $18.26B.
What was Merck & Co., Inc.'s cash & equivalents in 2023?
Merck & Co., Inc. annual cash & equivalents for 2023 was $6.91B, a 45.91% decline from 2022.
What was Merck & Co., Inc.'s cash & equivalents in 2022?
Merck & Co., Inc. annual cash & equivalents for 2022 was $12.77B, a 56.40% increase from 2021.
What is Merck & Co., Inc.'s 5-year cash & equivalents CAGR?
Merck & Co., Inc. cash & equivalents grew at a compound annual growth rate (CAGR) of 6.60% from FY2019 to FY2024, going from $9.68B to $13.32B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2024 | $13.32B | +92.8% | 10-K |
| FY2023 | $6.91B | -45.9% | 10-K |
| FY2022 | $12.77B | +56.4% | 10-K |
| FY2021 | $8.17B | +0.2% | 10-K |
| FY2020 | $8.15B | -15.7% | 10-K |
| FY2019 | $9.68B | +21.5% | 10-K |
| FY2018 | $7.97B | +30.7% | 10-K |
| FY2017 | $6.10B | -6.4% | 10-K |
| FY2016 | $6.51B | -23.6% | 10-K |
| FY2015 | $8.52B | +14.6% | 10-K |
| FY2014 | $7.44B | -52.4% | 10-K |
| FY2013 | $15.62B | +16.1% | 10-K |
| FY2012 | $13.45B | -0.6% | 10-K |
| FY2011 | $13.53B | +24.1% | 10-K |
| FY2010 | $10.90B | +17.1% | 10-K |
| FY2009 | $9.31B | +113.2% | 10-K |
| FY2008 | $4.37B | -18.1% | 10-K |
| FY2007 | $5.34B | -9.8% | 10-K |
| FY2006 | $5.91B | - | 10-K |